COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa) (PROfind)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03490032
Recruitment Status : Completed
First Posted : April 6, 2018
Last Update Posted : February 10, 2020
Information provided by (Responsible Party):
Advanced Accelerator Applications

Brief Summary:
Assessment of the safety and tolerability of a single administration of 3 mega Becquerel (MBq)/kg, but not less than 150 MBq and not more than 250 MBq, of 68Ga-PSMA-R2, to assess the pharmacokinetics (PK), biodistribution, and dosimetry of 68Ga-PSMA-R2, and to establish the optimal imaging method for determining location and burden of positive lesions in adult male patients with biochemical relapse (BR) and metastatic prostate cancer (mPCa).

Condition or disease Intervention/treatment Phase
Prostate Cancer Metastatic Drug: 68Ga-PSMA-R2 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

Phase I: characterize PK and dosimetry Phase II: diagnostic potential in 2 groups

  1. Prostate Cancer in biochemical relapse, and
  2. Metastatic Prostate Cancer
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase 1/2 Open-label, Multi-center, Safety and Tolerability Study of a Single Dose of 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
Actual Study Start Date : May 23, 2018
Actual Primary Completion Date : August 20, 2019
Actual Study Completion Date : September 13, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Phase I
PK and dosimetry following single dose 3 MBq/kg
Drug: 68Ga-PSMA-R2
radio-labelled PSMA ligand

Experimental: Phase II: Biochemically Recurrent Prostate Cancer
determine diagnostic effectiveness in this population
Drug: 68Ga-PSMA-R2
radio-labelled PSMA ligand

Experimental: Phase II: Metastatic Prostate Cancer
determine diagnostic effectiveness in this population
Drug: 68Ga-PSMA-R2
radio-labelled PSMA ligand

Primary Outcome Measures :
  1. Treatment Emergent Adverse Events [Safety and tolerability] [ Time Frame: dosing through 28 days post-dose ]

Secondary Outcome Measures :
  1. Generation of decay corrected tissue time-activity curves (TACs) from 68Ga-PSMA-R2 PET/CT images in normal organs and tumor lesions [ Time Frame: 0 to 4 hours post-dose ]
  2. Urinary excretion of 68Ga-PSMA-R2 [ Time Frame: 0 to 4 hours post-dose ]
  3. Calculation of half-life of 68Ga-PSMA-R2 in blood [ Time Frame: 0-4 hours post-dose ]
  4. Generation of non-decay-corrected time activity curves from 68Ga-PSMA-R2 PET/CT images in normal organs and tumor lesions [ Time Frame: 0-4 hours post-dose ]
  5. Calculation of residence times in organs and tumor lesions of 68Ga-PSMA-R2 [ Time Frame: 0-4 hours post-dose ]
  6. Calculation of 68Ga-PSMA-R2 absorbed dose [ Time Frame: 0-4 hours post-dose ]
  7. standard uptake value (SUV) [ Time Frame: 0-4 hours post-dose ]
  8. Calculation of patient level agreement of 68Ga-PSMA-R2 PET imaging relative to conventional techniques in prostate cancer patients [ Time Frame: 0-4 hours post-dose ]
  9. Calculation of and effective whole-body dose of 68Ga-PSMA-R2 [ Time Frame: 0-4 hours post-dose ]
  10. Tumor burden measured by 68Ga-PSMA-R2 compared with standard imaging modality [ Time Frame: 0-4 hours post-dose ]
  11. Tumor location compared to other standard imaging modality [ Time Frame: 0-4 hours post-dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male patients, 18 years of age or older.
  • Signed and dated written informed consent by the patient prior to any study-specific procedures.
  • Histologically confirmed adenocarcinoma of the prostate.

    1. Biochemical recurrence: defined as prostate specific antigen (PSA) level of ≥ 0.2 ng/mL after radical prostatectomy or PSA nadir plus 2 ng/mL after radiation therapy with corresponding CT/MRI or bone scan revealing absence of local recurrence or metastatic lesions.


    2. Metastatic disease: defined as both, castration-sensitive or castration-resistant mPCa (presence of at least one metastatic lymph-node, visceral metastasis and/or bone metastasis).
    3. At least 2 weeks must have elapsed between last anti-cancer treatment administration and the administration of the imaging product, 68Ga-PSMA-R2.
  • Prior major surgery must be at least 12 weeks prior to study entry.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2, with a life expectancy ≥ 6 months.
  • Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at Screening:

    • Hemoglobin (Hb): > 8.0 g/dL
    • Platelet count of > 50.000/mm3
  • Serum creatinine < 1.5 upper limit normal (ULN) or estimated glomerular filtration rate (eGFR) > 50 mL/min based upon The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [34].
  • For male patients with partners of childbearing potential, agreement to use barrier contraceptive method (condom) and to continue its use for 28 days after IP administration.

Exclusion Criteria:

  • Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate or any other histologies different than adenocarcinoma.
  • Administered a radioisotope ≤ 10 physical half-lives prior to the day of PET/CT.
  • Current severe urinary incontinence, hydronephrosis, severe voiding dysfunction, or need of indwelling/condom catheters.
  • Uncontrolled pain or incompatibility that results in patient's lack of compliance with imaging procedures
  • Other known co-existing malignancies except non-melanoma skin cancer unless definitively treated and proven no evidence of recurrence for at least 5 years.
  • Patient with known incompatibility to CT scans.
  • Any evidence of severe or uncontrolled systemic or psychiatric diseases, including uncontrolled hypertension and active bleeding diatheses, which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or active infection including human immunodeficiency virus (HIV) and untreated hepatitis B, hepatitis C. Screening for chronic conditions is not required.
  • Patients who have received any investigational agent within the last 28 days are excluded from participation in this trial.
  • Any acute toxicity due to prior chemotherapy and/or radiotherapy that has not resolved according to the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
  • Known allergy, hypersensitivity, or intolerance to the investigational product or its excipients.
  • Patient unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03490032

Layout table for location information
United States, Arizona
Pheonix Molecular Imaging Center
Phoenix, Arizona, United States, 85040
United States, California
University of California, San Francisco (UCSF)
San Francisco, California, United States, 94158
United States, Connecticut
Smilow Cancer Center at Yale New Haven
New Haven, Connecticut, United States, 06510
United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
National Institutes of Health, Warren Grant Magnusen Clinical Center
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Advanced Accelerator Applications
Layout table for investigator information
Study Director: Study Director Advanced Accelerator Applications
Layout table for additonal information
Responsible Party: Advanced Accelerator Applications Identifier: NCT03490032    
Other Study ID Numbers: A206D-A01-001
CAAA502A12101 ( Other Identifier: Novartis )
First Posted: April 6, 2018    Key Record Dates
Last Update Posted: February 10, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases